Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22018249 | 0.88 | MEN1 (0.32) | LMNA | |
| SCHEMBL22018248 | 0.75 | — | — | |
| SCHEMBL4875346 | 0.65 | LMNA (0.39) | LMNATP53 | |
| SCHEMBL2408989 | 0.61 | LMNA (0.36) | LMNA | |
| SCHEMBL11272034 | 0.61 | AKR1B1 (0.34) | — | |
| SCHEMBL9699902 | 0.60 | — | — | |
| SCHEMBL4379931 | 0.59 | LMNA (0.35) | LMNA | |
| SCHEMBL4386817 | 0.59 | LMNA (0.35) | LMNA | |
| SCHEMBL20956935 | 0.59 | — | — | |
| SCHEMBL20807859 | 0.59 | CRBN (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11185592-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | LMNA 1938/4885TP53 223/4885 |
| US-20210106688-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | LMNA 1938/4885TP53 223/4885 |
| US-10660968-B2 | Spirocyclic degronimers for target protein degradation | STUB1, UBE3C, UBE3A | LMNA 1938/4885TP53 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.